CleoCare, a pioneering Portuguese femtech startup, will bring its innovative breast health tech and perspective to Capitol Hill on July 16, joining major stakeholders to support improved early breast cancer detection policies.
As Forbes Portugal reports, CleoCare recently joined the Breast Cancer Early Detection Coalition (BCEDC), an alliance on a mission to expand access to effective, accurate breast cancer screening. The coalition’s initiatives include the Find It Early Act, a bipartisan bill it is actively championing in Congress.
This milestone grants CleoCare a seat at the table during legislative discussions on Capitol Hill, alongside members of Congress, doctors, and public health experts.
The mission of CleoCare aligns closely with the coalition’s goals, focusing on improving access to early detection tools and increasing breast health awareness.
Founded in 2021 by Francisco Nogueira and Frederico Stock, both honored as Forbes Portugal 30 Under 30, CleoCare has developed SenseGlove, a home medical device designed to revolutionize breast health monitoring.
The portable glove, paired with an intuitive app, enables women to perform smarter and more accurate breast self-exams in under five minutes from the comfort of home.
SenseGlove sends users reminders when it’s time for their monthly self-checks and guides them step-by-step during the exam. Its built-in sensors detect changes in breast tissue while the app analyzes the data and generates reports that can be shared with healthcare providers.
If abnormalities are detected, CleoCare’s medical team recommends timely in-person follow-up. The technology is designed to complement, not replace, regular clinical screenings, enhancing accessibility and consistency in preventive care.
Breast cancer is the most common cancer in women and the second most common overall. According to the World Health Organization’s specialized agency, the International Agency for Research on Cancer (IARC), cases are expected to rise by 38% globally by 2050, while annual deaths from the disease are projected to increase by 68%.
Detecting cancer early significantly improves the likelihood of successful treatment. There are two main approaches to early detection: early diagnosis and screening. Early diagnosis involves identifying cancer in individuals who already show symptoms, aiming to catch the disease at the earliest possible stage. Screening, on the other hand, targets individuals without symptoms, using tests to uncover cancer before any signs develop.
Nogueira, CEO of CleoCare, formerly known as Glooma, told Forbes Portugal, “We believe that breast health begins long before any diagnosis. Being in this coalition is a natural extension of our purpose: to make knowledge and tools accessible to all women at all stages of life.”
Stock adds that presenting their award-winning innovation on Capitol Hill is “a great step for us as we work to advance early detection and women’s health.”
Featured image: SenseGlove is a portable, home-based medical device that complements breast self-examinations. (Photo Courtesy of CleoCare)
Portugal Startup News 
One response to “CleoCare takes early breast cancer detection tech to Capitol Hill”
[…] and Francisco Neto Nogueira, both honored as Forbes Portugal 30 Under 30, CleoCare has developed SenseGlove, a home medical device designed to revolutionize breast health […]